Objective To study the therapeutic effect of TK/GCV in the treatment of acute graft-versus-host disease in H-2 haploidentical mice induced by CD34 + cells mixed with TK + T lymphocytes transplantation.Methods CD34 + cells were separated from male parental donors,bone marrows,meanwhile T lymphocytes were gained from their spleens and transduced by retroviral vectors comprising TK gene. Both were mixed and transfused into female F1 recipient mice,CD34 + cells and TK + T lymphocytes each F1 recipient mouse received were 1?10 5 and 1?10 7,respectively. GCV was administered at the dosage of 50 mg ?kg -1 ?day -1 for 7 by intraperitoneal injections on the day 0 or 7 after transplantation.Results Acute GVHDs appeared in all mice. Survival time of the mice treated with GCV on the day 0 or 7 after transplantation was ( 26.6 ? 4.8 ) days and ( 40.5 ? 8.4 ) days,respectively. Therapeutic effect of GCV on the day 7 posttransplantation was better than that on the day 0 posttransplantation ( P

Objective To summarize the experience of improved nonmyeloablative hematopoietic stem cell transplantation(NSCT) in the treatment of severe aplastie anemia. Methods Seventeen patients with Severe Aplastic Anemia received NSCT after a nonmyeloablative conditioning.The patients were conditioned with decreased dosage of immunosuppressive agents of CTX and anti-lymphoid cell globulin or anti-thymus gland cell globulins;CsA and MMF were used to prevent the graft-versus-host disease (GVHD) after transplantation. Results 75 % of severe aplastic anemia in patients with type Ⅰ and 60 % of severe aplastic anemia in patients with type Ⅱ achieved rapid hematopoietic reconstitution, with good prognosis and implantation rate with fewer complieations and light symptoms were observed. Conclusion NSCT is an effective treatment of severe aplastic anemia.

Humans ; Asthma/diagnosis* ; HMGB1 Protein

Chronic obstructive pulmonary disease (COPD) has become the third-leading cause of death worldwide, which is a severe economic burden to the healthcare system. Chronic bronchitis is the most common condition that contributes to COPD, both locally and systemically. Neutrophilic inflammation predominates in the COPD airway wall and lumen. Logically, repression of neutrophilia is an essential fashion to COPD treatment. However, currently available anti-neutrophilic therapies provide little benefit in COPD patients and may have serious side effects. Thus, there is an urgent need to explore an effective and safe anti-neutrophilic approach that might delay progression of the disease. Sialic acid-binding immunoglobulin-like lectin (Siglec)-9 is a member of the Siglec cell surface immunoglobulin family. It is noteworthy that Siglec-9 is highly expressed on human neutrophils and monocytes. Ligation of Siglec-9 by chemical compounds or synthetic ligands induced apoptosis and autophagic-like cell death in human neutrophils. Furthermore, administration of antibody to Siglec-E, mouse functional ortholog of Siglec-9, restrained recruitment and activation of neutrophils in mouse models of airway inflammation in vivo. Given the critical role that neutrophils play in chronic bronchitis and emphysema, targeting Siglec-9 could be beneficial for the treatment of COPD, asthma, fibrosis, and related chronic inflammatory lung diseases.
Animals ; Asthma ; Humans ; Lung ; Mice ; N-Acetylneuraminic Acid ; Neutrophils ; Pulmonary Disease, Chronic Obstructive/drug therapy* ; Sialic Acid Binding Immunoglobulin-like Lectins